



and approval by the Pharmacy & Therapeutics Committee of the criteria for prior authorization, as described in RX.003-Prior Authorization Process.

The drug, Lyrica (pregabalin), is subject to the prior authorization process.

## **PROCEDURE**

### **Initial Authorization Criteria:**

*Must meet all of the criteria listed under the respective diagnosis:*

#### **1. Fibromyalgia**

- Must have chart documentation showing the diagnosis of fibromyalgia with a history of widespread pain involving the extremities for three months and localized area of tenderness
- Must have a trial and failure of the following agents unless there is documented intolerance or contraindication:
  - Gabapentin (Neurontin) at a dose of at least 1200 mg daily which is documented in pharmacy claims or through physician chart documentation
  - Tricyclic antidepressants (i.e., amitriptyline) **OR** muscle relaxants (i.e., cyclobenzaprine)
- Must have physician chart documentation showing trial of exercise or physical therapy.

#### **2. Postherpetic Neuralgia**

- Must have a trial and failure of one of the following agents unless there is a documented contraindication: tricyclic antidepressants (i.e., amitriptyline) or gabapentin (Neurontin).

#### **3. Diabetic Peripheral Neuropathy**

- Must have a documented pharmacy claim history of prior therapy with a diabetic medication or a medical claim/lab claim for the diagnosis of diabetes or must have physician chart documentation of diagnosis of diabetes
- Must have a trial and failure of gabapentin (Neurontin) unless there is a documented contraindication

#### **4. Seizure Disorders**

- Must be prescribed by or in consultation with a neurologist
- Must have a diagnosis of partial onset seizures
- Must be using Lyrica as an adjunctive therapy to other antiepileptic drugs (AEDs)



- Must have had an inadequate response or intolerance to at least 2 generic antiepileptic medications

**5. Neuropathic Pain from Spinal Cord Injury**

- Must have a trial and failure of the following agents:
  - Gabapentin (Neurontin) at a dose of at least 2400mg daily unless there is intolerance despite slow dose titration or contraindication
  - Tricyclic antidepressant (i.e., amitriptyline) unless there is documented intolerance or contraindication

**Limitations:**

<b>Length of Authorization (if above criteria met)</b>	
Initial Authorization	Up to duration of member’s membership with plan
Reauthorization	N/A
<b>Quantity Limits</b>	
25mg, 50mg, 75mg, 100mg, 150mg, 200mg	90 capsules per month
225mg, 300mg	60 capsules per month
20mg/mL solution	900 mL per 30 days

If the established criteria are not met, the request is referred to a Medical Director for review.

**REFERENCES**

1. Lyrice [package insert]. Pfizer: Vega Baja, PR; June 2012.
2. Dubinsky RM, Kabbani H, El-Chami Z, et al. Practice Parameter: Treatment of Postherpetic Neuralgia. An evidence-based report of the quality standards subcommittee of the American Academy of Neurology. *Neurology*. 2004; 63:959-965.
3. American Diabetes Association. Position Statement: Standards of Medical care in Diabetes-2006. *Diabetes Care*. 2006; 29(S1):S4-S42.
4. Goldenberg DL, Burckhardt C, Crofford L. Management of Fibromyalgia Syndrome: An evidence-based guideline for the optimal treatment of Fibromyalgia. *JAMA*. 2004; 292(19):2388-2395.
5. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. *Arthritis & Rheumatism* 2007;56(4):1336-1344.
6. Siddall PJ, Cousins MJ, Otte A, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. *Neurology* 2006;67:1792-1800.



***Lyrica (pregabalin)***

**POLICY NUMBER: RX.PA.045.E**

**REVISION DATE: 10/17**

**PAGE NUMBER: 4 of 4**

7. To T-P, Lim TC, Hill ST, et al. Gabapentin for neuropathic pain following spinal cord injury. *Spinal Cord* 2002;40:282-285.
8. Levendoglu F, Ogun C, Ozebril O, et al. Gabapentin is a first-line drug for the treatment of neuropathic pain in spinal cord injury. *Spine* 2004;29,7:743-751.
9. Rintala D, Holmes SA, Courtade D, et al. Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. *Journal Arch Phys Med Rehabil* 2007;88:1547-60.
10. Multidisciplinary Association of Spinal Cord Injury Professionals. Guidelines for the Management of Neuropathic Pain in Adults following Spinal Cord Injury. 2nd edition. November 2008.

**RECORD RETENTION**

Records Retention for Evolent Health documents, regardless of medium, are provided within the Evolent Health records retention policy and as indicated in CORP.028.E Records Retention Policy and Procedure.

**REVIEW HISTORY**

<b>DESCRIPTION OF REVIEW / REVISION</b>	<b>DATE APPROVED</b>
<i>Annual Review</i>	<i>02/16, 02/17, 02/18</i>
<i>Criteria Update</i>	<i>10/17</i>

